Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 9/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39349 | 0.90 | PDK4 (0.43) | USP30PDK4GRM5GRM1NAMPT | |
| Carbamic Acid SCHEMBL30167549 | 0.86 | GRM5 (0.41) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL986465 | 0.83 | P2RX7 (0.44) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL12194027 | 0.83 | GRM5 (0.45) | PDK4GRM5GRM1NAMPTNR1H2 | |
| SCHEMBL20131001 | 0.83 | PDK4 (0.40) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL22539474 | 0.82 | P2RX7 (0.39) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL19373550 | 0.82 | PDK4 (0.39) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL20998704 | 0.81 | PDK4 (0.41) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL18409255 | 0.81 | PDK4 (0.39) | USP30PDK4GRM5GRM1NAMPT | |
| SCHEMBL10179664 | 0.80 | P2RX7 (0.46) | USP30PDK4NR1H2P2RX7ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | USP30 4486/4885PDK4 210/4885GRM5 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.